Biotech Values

[dewophile]

Approval for GSK and PFE always seemed highly likely and ACIP in June more of the wild card. Will they green light only in 65 and older vs 60, etc. The other wild card is negotiations w retailers. GSK has the upper hand this flu season bc assuming ACIP green lights for high risk adults under 65 they will be the only ones w data in 50-59 year olds (as well as all 3 flu coadministration groups regular, high dose, and adjuvenated). So it is hard for a large pharmacy chain where half or more of vaccinations take place these days to not carry the GSK product, and presumably some may only want to carry one. Next year RSV season presumably will also have moderna - PFE and GSK will have efficacy data from a second season so they will be playing from behind wrt to this, but longer term who knows how the relative market shares shake out. PFE has the edge on tolerability, GSK/MRNA efficacy, and if covid becomes an annual shot I think having a flu/covid 2 in 1 could make a difference. PFE mentioned that they are seeing good efficacy in the second season so including RSV becomes less important if that is an every 2-3 year shot vs flu/covid